# US 2008/0269282 A1 · Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0269282 A1
- Document ID: US20080269282A1
- Status: Published application
- Kind: A1
- Application number: 11/573,089
- Filed: 2005-08-02
- Published: 2008-10-30
- Earliest claimed: 2004-08-02
- Assignees: Genmedica Therapeutics Sl
- Inventors: Luc Marti Clauzel; Silvia Garcia Vicente; Francesc Yraola Font; Miriam Royo Exposito; Fernando Albericio Palomera; Antonio Zorzano Olarte
- Web page: https://patentgrep.com/patent/US20080269282A1

## CPC

- C07D 207/16: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 233/51: having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
- C07C 237/44: having carbon atoms of carboxamide groups, amino groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C 259/06: having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C 259/08: having carbon atoms of hydroxamic groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C 259/10: having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
- C07D 209/18: Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 209/42: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 215/36: Sulfur atoms (C07D215/24 takes precedence)
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07C 2601/08: the ring being saturated
- C07C 2602/08: the other ring being five-membered, e.g. indane
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

This invention is directed to inhibitors of copper-containing amine oxidases (E.C.1.4.3.6) including semicarbazide-sensitive amine oxidase (SSAO; also known as vascular adhesion protein-1, VAP-I), and their therapeutic use in inflammatory diseases, diabetes and its associated complications, atherosclerosis, neurodegenerative diseases, obesity, hypertension and cancer.

## Claims

### Claim at position 1

1-42. (canceled)

### Claim 43

A compound of formula:
R3—(Y)n—(CR2R2)m-Z
or a pharmaceutically acceptable salt thereof, wherein
m is 1-4;
n is 1;
Z is CONR10H;
Y is —C(O)NH—;
R1 is independently H or C1-C6 alkyl;
R2 is independently H or C1-C6 alkyl, wherein the C1-C6 alkyl is optionally substituted with OH, NH2, or SH; and
R3 is aryl selected from phenyl, naphthyl, indanyl, and biphenyl, C5-C6 cycloalkyl, heteroaryl
selected from pyridyl, pyrimidyl, indolyl, pyrrolyl, thienyl, furanyl, thiazolyl, pyrazolyl,
and oxazolyl, heterocycloalkyl selected from piperazinyl, piperidinyl, pyrrolidinyl,
quinolinyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, and
S,S-dioxothiomorpholinyl, each of which is optionally substituted with 1, 2, 3, 4, or 5 groups that are independently C1-C6 alkyl, C1-C6 alkoxy, halogen, CF3, OCF3, nitro, CN, CO2H, C1-C6 alkylthio, C1-C6 acyloxy, phenyl, pyridyl, thienyl, furanyl, pyrimidyl, or hydroxy.

### Claim 44 (depends on 43)

The compound according to claim 43 that is N1-hydroxy-N2-[(4-bromophenyl)carbonyl]glycinamide.

### Claim 45

A compound of formula
wherein
R10 and R20 are independently H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, substituted aryl, heterocycloalkyl containing one or two heteroatoms selected from S, N, and O, or C3-C7 cycloalkyl, and where any member of the alkyl, aryl, or cycloalkyl group is optionally substituted with halogen, C1-C6 alkyl or C1-C6 alkoxy, aryl or substituted aryl;
R30 and R40 are independently H, OH, SH, halogen, nitro, amino, mono or di(C1-C6 alkyl)amino, C1-C6 alkyl, C1-C6 alkanoyl, aryl, substituted aryl, C1-C6 alkoxy, C1-C6 alkoxyalkyl, C3-C7 cycloalkyl, C3-C7 cycloalkylalkyl, C3-C7 cycloalkylalkoxy, heteroaryl, heteroarylalkyl, heterocycloalkyl, or heterocycloalkylalkyl, where the cyclic portion, the alkyl portion or a combination thereof of each of the above is optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen, C1-C6 alkyl, C1-C6 alkoxy, aryl, substituted aryl, halogen, nitro, nitroso, aldehyde, carboxylic acid, —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)(C1-C6 alkyl), amino, mono or di(C1-C6 alkyl)amino, C1-C6 alkoxycarbonyl, sulfate, imine, hydroxyl or nitrile;
Y1 is (CH2), or aryl;
m is 0, 1, 2, 3, or 4;
n is 0, 1, 2, 3, or 4;
W is NHOH, NH2, NHR10, OR10, or NH—NHR10;
X1 and X2 are independently C, CH, or N, provided that X1 and X2 are not simultaneously N;
where the dashed lines represent a cycloalkyl or aryl group that is optionally present; and
n and m independently an integer from 1 to 5.

### Claim 46 (depends on 45)

The compounds according to claim 45 wherein m is 0.

### Claim 47 (depends on 46)

The compounds according to claim 46 wherein R30 and R40 are independently H, OH, SH, halogen, nitro, amino, mono or di(C1-C6 alkyl)amino, C1-C6 alkyl, C1-C6 alkanoyl, or C1-C6 alkoxy.

### Claim 48 (depends on 47)

The compounds according to claim 47 wherein Y1 is (CH2)n, and n is 0, 1, or 2.

### Claim 49 (depends on 48)

The compounds according to claim 48 wherein W is NHOH.

### Claim 50 (depends on 45)

The compounds according to claim 45 selected from
N-hydroxy-N′-(1-methyl-3-phenylpropyl)succinamide;
N-hydroxy-N′-(2-hydroxyphenyl)succinamide; and
N1-hydroxy-N4-(1-(naphthalen-2-yl)ethyl)succinamide.

### Claim 51

A compound of formula
wherein
n is an integer from 1 to 5;
R10 is independently H, C1-C6 alkyl, aryl, C2-C6 alkenyl, C2-C6alkynyl, substituted aryl, heterocycloalkyl containing one or two heteroatoms selected from S, N, and O, or C3-C7 cycloalkyl, and where any member of the alkyl, aryl, or cycloalkyl group is optionally substituted with halogen, C1-C6 alkyl, C1-C6 alkoxy, aryl, or substituted aryl;
R20 is H, C1-C6 alkyl, aryl, substituted aryl, C1-C6 alkoxy, C1-C6 alkoxyalkyl, C3-C7 cycloalkyl, C3-C7 cycloalkylalkyl, C3-C7 cycloalkylalkoxy, heteroaryl, heteroarylalkyl, heterocycloalkyl, or heterocycloalkylalkyl, where each of the above is optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen, C1-C6 alkyl, C1-C6 alkoxy, aryl, arylalkoxy, substituted aryl, halogen, nitro, nitroso, aldehyde, carboxylic acid, —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)(C1-C6 alkyl), amino, C1-C6 alkoxycarbonyl, sulfate, imine, hydroxyl or nitrile; or
R10, R20 and the carbon to which they are attached form a cycloalkyl ring;
R40 is H, C1-C6 alkyl, aryl, substituted aryl, C1-C6 alkoxy, C1-C6 alkoxyalkyl, C3-C7 cycloalkyl, C3-C7 cycloalkylalkyl, C3-C7 cycloalkylalkoxy, heteroaryl, heteroarylalkyl, heterocycloalkyl, or heterocycloalkylalkyl, where each of the above is optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen, C1-C6 alkyl, C1-C6 alkoxy, aryl, arylalkoxy, substituted aryl, halogen, nitro, nitroso, aldehyde, carboxylic acid, —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)(C1-C6 alkyl), amino, C1-C6 alkoxycarbonyl, sulfate, imine, hydroxyl or nitrile; or
Y1 is SO2, C(O), CH2, or —NHC(O); and
W is NHOH, NHR10, OR10, or NH—NHR10.

### Claim 52 (depends on 51)

The compounds according to claim 51 wherein R40 is phenyl, naphthyl, furanyl, indolyl, or quinolinyl, where each of the above is optionally substituted with 1, 2, or 3 groups that are independently halogen, C1-C6 alkyl, C1-C6 alkoxy, phenyl, halogen, nitro, carboxylic acid, —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)(C1-C6 alkyl), amino, C1-C6 alkoxycarbonyl, hydroxyl or nitrile.

### Claim 53 (depends on 52)

The compounds according to claim 52 wherein n is 1 or 2 and R10 and R20 are both H.

### Claim 54 (depends on 52)

The compounds according to claim 52 wherein R10, R20 and the carbon to which they are attached form a cycloalkyl ring and W is NHOH.

### Claim 55 (depends on 51)

The compounds according to claim 51 selected from
N-hydroxy-4-[({[1-(4-methylphenyl)cyclopentyl]carbonyl}amino)methyl]benzamide;
and
N-hydroxy-4-({[3-(2-hydroxyphenyl)propanoyl]amino}methyl)benzamide.

### Claim 56

A compound of formula
wherein
n is an integer from 1 to 5;
R10 is independently H, C1-C6 alkyl, aryl, C2-C6 alkenyl, C2-C6alkynyl, substituted aryl,
heterocycloalkyl containing one or two heteroatoms selected from S, N, and O, or
C3-C7 cycloalkyl, and where any member of the alkyl, aryl, or cycloalkyl group is optionally substituted with halogen, C1-C6 alkyl or C1-C6 alkoxy, aryl or substituted aryl;
R20 is independently H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, substituted aryl, heterocycloalkyl containing one or two heteroatoms selected from S, N, and O, or C3-C7 cycloalkyl, and where any member of the alkyl, aryl, or cycloalkyl group is optionally substituted with halogen, C1-C6 alkyl or C1-C6 alkoxy, aryl or substituted aryl;
R30 is independently H, C1-C6 alkyl, aryl, substituted aryl, C1-C6 alkoxy, C1-C6 alkoxyalkyl, C3-C7 cycloalkyl, C3-C7 cycloalkylalkyl, C3-C7 cycloalkylalkoxy, heteroaryl, heteroarylalkyl, heterocycloalkyl, or heterocycloalkylalkyl, where each of the above is optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen, C1-C6 alkyl, C1-C6 alkoxy, aryl, substituted aryl, halogen, nitro, nitroso, aldehyde, carboxylic acid, —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)(C1-C6 alkyl), amino, C1-C6 alkoxycarbonyl, sulfate, imine, hydroxyl or nitrile; or
R20, R30, and the carbon to which they are attached form a cycloalkyl ring; or
optionally encompasses olefins when n is 2-5, in such a case, R20 is not present on the olefinic carbons.
R40 is H, C1-C6 alkyl, aryl, substituted aryl, C1-C6 alkoxy, C1-C6 alkoxyalkyl, C3-C7 cycloalkyl, C3-C7 cycloalkylalkyl, C3-C7 cycloalkylalkoxy, heteroaryl, heteroarylalkyl, heterocycloalkyl, or heterocycloalkylalkyl, where each of the above is optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen, C1-C6 alkyl, C1-C6 alkoxy, aryl, substituted aryl, halogen, nitro, nitroso, aldehyde, carboxylic acid, —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)(C1-C6 alkyl), amino, C1-C6 alkoxycarbonyl, sulfate, imine, hydroxyl or nitrile;
Y1 is CH2, C(O), or SO2; and
W at each occurrence is independently NHOH, NHR10, OR10, or NH—NHR10.

### Claim 57 (depends on 56)

The compounds according to claim 56 wherein Y1 is C(O).

### Claim 58 (depends on 57)

The compounds according to claim 57 wherein R40 is phenyl, indolyl, or furanyl, where each of the above is optionally substituted with 1, 2, or 3 groups that are independently halogen, C1-C6 alkyl, C1-C6 alkoxy, aryl, halogen, nitro, carboxylic acid, —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)(C1-C6 alkyl), amino, C1-C6 alkoxycarbonyl, hydroxyl or nitrile.

### Claim 59 (depends on 57)

The compounds according to claim 57 wherein when n is 2;
is a C2 olefin; R20 is absent and R30 is H or C1-C4 alkyl.

### Claim 60 (depends on 57)

The compounds according to claim 57 wherein R20, R30, and the carbon to which they are attached form a cycloalkyl ring and at least one W is OH.

### Claim 61 (depends on 56)

The compounds according to claim 56 selected from
N-(biphenyl-4-ylacetyl)glutamic acid;
N5-hydroxy-N2-{[1-(4-methylphenyl)cyclopentyl]carbonyl}glutamine;
N-(4-phenylbutanoyl)glutamic acid;
N-[4-(4-methylphenyl)butanoyl]glutamic acid; and
N-[(2E)-3-(4-methylphenyl)prop-2-enoyl]glutamic acid.

### Claim 62

A compound of formula
wherein
R20 and R30 are independently H, C1-C6 alkyl, aryl, substituted aryl, heterocycloalkyl containing one or two heteroatoms selected from S, N, and O, or C3-C7 cycloalkyl, and where any member of the alkyl, aryl, or cycloalkyl group is optionally substituted with halogen, OH, SH, C1-C6 alkyl or C1-C6 alkoxy, aryl, or substituted aryl;
W is NHOH, NHR10, OR10, or NH—NHR10;
X is C, CH, or any heteroatom selected from S, N, and O;
Y1 is CO, or CH2; and
the dashed lines represent an optional aryl, heteroaryl or heterocycloalkyl ring.

### Claim 63 (depends on 62)

The compounds according to claim 62 wherein Y1 is CO.

### Claim 64 (depends on 63)

The compounds according to claim 63 wherein
is phenyl, naphthyl, pyridyl, or quinolinyl, each of which is optionally substituted with 1, 2, or 3 groups that are independently OH, SH, C1-C4 alkyl, C1-C4 alkoxy, or phenyl.

### Claim 65 (depends on 62)

The compounds according to claim 62 wherein W is NHOH or NH2.

### Claim 66 (depends on 62)

The compounds according to claim 62 selected from
1-(biphenyl-4-ylcarbonyl)prolinamide;
1-(4-tert-butylbenzoyl)prolinamide;
1-(3-hydroxy-2-naphthoyl)prolinamide; and
1-(quinolin-6-ylcarbonyl)prolinamide.

### Claim 67

A compound of formula
wherein
R10 and R20 are independently H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, substituted aryl, heterocycloalkyl containing one or two heteroatoms selected from S, N, and O, or C3-C7 cycloalkyl, and where any member of the alkyl, aryl, or cycloalkyl group is optionally substituted with halogen, C1-C6 alkyl or C1-C6 alkoxy, aryl or substituted aryl.

### Claim 68 (depends on 67)

The compounds according to claim 67 wherein R10 is H or C1-C4 alkyl.

### Claim 69 (depends on 68)

The compounds according to claim 68 wherein R20 is C1-C6 alkyl substituted with phenyl or naphthyl, where each is optionally substituted with 1 or 2 groups that are independently OH, halogen, C1-C4 alkyl, or C1-C4 alkoxy.

### Claim 70 (depends on 67)

The compounds according to claim 67 selected from
5-amino-N-benzyl-2-hydroxybenzamide;
5-amino-2-hydroxy-N-(2-hydroxybenzyl)benzamide;
5-amino-N-(4-fluorobenzyl)-2-hydroxybenzamide;
5-amino-N-(3,5-dimethoxybenzyl)-2-hydroxybenzamide;
5-amino-2-hydroxy-N-(2-naphthylmethyl)benzamide;
5-amino-2-hydroxy-N-(2-phenylethyl)benzamide;
5-amino-2-hydroxy-N-(3-phenylpropyl)benzamide; and
5-amino-2-hydroxy-N-(4-phenylbutyl)benzamide.

### Claim 71

A compound of formula
wherein
R20 is —CH2—X, —CH2CH2—X, —CH(CH3)—X, —CH2CH2CH2—X, —CH2CH2CH2CH2—X or —CH2CH2—O—X; and
X is phenyl or naphthyl optionally substituted with 1 or 2 groups selected from methoxy, —F, or —OH.

### Claim 72 (depends on 71)

The compounds according to claim 71 selected from
4-amino-N-(4-fluorobenzyl)-3-hydroxybenzamide;
4-amino-3-hydroxy-N-(2-naphthylmethyl)benzamide;
4-amino-3-hydroxy-N-(2-phenoxyethyl)benzamide;
4-amino-3-hydroxy-N-[1-(2-naphthyl)ethyl]benzamide;
4-amino-3-hydroxy-N-(2-phenylethyl)benzamide;
4-amino-3-hydroxy-N-(3-phenylpropyl)benzamide; and
4-amino-3-hydroxy-N-(4-phenylbutyl)benzamide.

### Claim 73

The compound N-hydroxy-2-(2-(2-methyl-1H-indol-3-yl)acetamido)acetamide.

### Claim 74

The compound N-hydroxy-4-({[(4-methylphenyl)sulfonyl]amino}methyl)benzamide.

### Claim 75

The compound N-(1H-indol-2-ylcarbonyl)glutamic acid.

### Claim 76

The compound 1-(isoquinolin-1-ylcarbonyl)prolinamide.

### Claim 77

The compound 5-amino-2-hydroxy-N-(2-phenoxyethyl)benzamide.

### Claim 78

The compound selected from
N2-(biphenyl-4-ylsulfonyl)-N1-hydroxythreoninamide;
3-amino-N2-(biphenyl-4-ylsulfonyl)-N1-hydroxyalaninamide;
N1-hydroxy-N2-[(4-propylphenyl)sulfonyl]serinamide;
N1-hydroxy-N2-[(4-propylphenyl)sulfonyl]threoninamide;
N2-{[4-(1,1-dimethylpropyl)phenyl]sulfonyl}-N1-hydroxyserinamide;
N2-{[4-(1,1-dimethylpropyl)phenyl]sulfonyl}-N1-hydroxythreoninamide;
N2-{[4-(1,1-dimethylpropyl)phenyl]sulfonyl}-N1-hydroxyglycinamide;
N1-hydroxy-N2-(2-naphthylsulfonyl)serinamide;
N1-hydroxy-N2-(2-naphthylsulfonyl)threoninamide;
N1-hydroxy-N2-[(4-methyl-3-nitrophenyl)sulfonyl]serinamide;
N1-hydroxy-N2-(2-naphthylsulfonyl)glycinamide;
N1-hydroxy-N2-[(4-methylphenyl)sulfonyl]threoninamide;
3-amino-N1-hydroxy-N2-[(4-methylphenyl)sulfonyl]alaninamide;
N1-hydroxy-N2-(quinolin-7-ylsulfonyl)threoninamide;
N2-{[8-(dimethylamino)-2-naphthyl]sulfonyl}-N1-hydroxyserinamide; and
N2-{[8-(dimethylamino)-2-naphthyl]sulfonyl}-N1-hydroxythreoninamide.

### Claim 79

A method of treating an animal having a disease or disorder characterized by pathological expression of a copper-containing amine oxidase enzyme, comprising administering to an animal in need of such treatment an inhibitor of said copper-containing amine oxidase at a therapeutically-active concentration, wherein the inhibitor is a compound of formula
R3—(Y)n—(CR2R2)m-Z
or a pharmaceutically acceptable salt thereof, wherein
m is 0 or 1-6;
n is 0 or 1;
Z is CONR10H, COOH, B(OH)2, SO2NR1OH, OR1, SR1, NHR1, PO3H, CH2NHR1, COR1, CONHR1, CHNR1, or CNR1NHR1;
Y at each occurrence is independently —CO—, —CS—, —NR2OR2—, —NR2—, —SR2—, —NR2SO2R2—, —COR2—, —NR2—C(NR2)—NR2—, —(C1-C6 alkyl)-NHC(O)—, —(C1-C6 alkyl)-N(C1-C6 alkyl)C(O)—, —NHC(O)—(C1-C6 alkyl)-, —N(C1-C6 alkyl)C(O)—(C1-C6 alkyl)-, —NHC(O)—, —N(C1-C6alkyl)C(O)—, —C(O)NH—, —C(O)—N(C1-C6alkyl), —SO2NH—, —SO2—N(C1-C6alkyl)-, —(C1-C6 alkyl)-C(O)NH—, —(C1-C6 alkyl)-C(O)—N(C1-C6alkyl)-, —O—(C1-C6 alkyl)-NHC(O)—, or —O—(C1-C6 alkyl)-N(C1-C6 alkyl)C(O)—, wherein the alkyl portion or portions of each of the above is optionally substituted with 1, 2, or 3 groups that are independently halogen, C1-C4 alkoxy, amino, mono or di (C1-C6 alkyl)amino, OH, indolyl, pyrrolyl, pyridyl, furanyl, guanidinyl, carboxyl, or ═O;
R1 at each occurrence is independently H, C1-C6 alkyl, aryl, substituted aryl, heterocycloalkyl containing at least one and no more than two heteroatoms selected from S, N, and O, or C3-C7 cycloalkyl, and where any member of the alkyl, aryl/or cycloalkyl group is optionally substituted with halogen, C1-C6 alkyl or C1-C6 alkoxy, aryl or substituted aryl;
R2 at each occurrence is independently H, C1-C6 alkyl, carboxyl, C1-C6 alkoxycarbonyl, aryl, substituted aryl, C1-C6 alkoxy, C1-C6 alkoxyalkyl, C3-C7 cycloalkyl, C3-C7 cycloalkylalkyl, C3-C7 cycloalkylalkoxy, heteroaryl, heteroarylalkyl, heterocycloalkyl, or heterocycloalkylalkyl, where each of the above is optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen, C1-C6 alkyl, C1-C6 alkoxy, aryl, substituted aryl, halogen, nitro, nitroso, aldehyde (CHO), carboxylic acid, —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)(C1-C6 alkyl), amino, NH(C1-C6 alkyl), N(C1-C6 alkyl)(C1-C6 alkyl), C1-C6 alkoxycarbonyl, sulfate, imine, hydroxyl, —SH, or nitrile; and R3 is aryl, C1-C6 alkyl, C2-C4 alkenyl, C3-C7 cycloalkyl, C3-C7 cycloalkyl C1-C6 alkyl, C3-C7 cycloalkyl C1-C6 alkoxy, heteroaryl, heterocycloalkyl, each of which is optionally substituted with 1, 2, 3, 4, or 5 groups that are independently C1-C6 alkyl, C1-C6 alkoxy, halogen, haloalkyl, haloalkoxy, nitro, amino, NH(C1-C6 alkyl), N(C1-C6 alkyl)(C1-C6 alkyl), CN, CO2H, C1-C6 alkylthio, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C6 acyloxy, aryl, heteroaryl, or hydroxyl, where the aryl and heteroaryl substituents on R3 are further optionally substituted with one or more groups that are independently C1-C6 alkyl, amino, NH(C1-C6 alkyl), N(C1-C6 alkyl)(C1-C6 alkyl), OH, NO2, C1-C6 alkoxy, halogen, arylalkoxy (in one aspect, phenylalkoxy, in another aspect, phenylCl alkoxy), haloalkyl (in one aspect, CF3), haloalkoxy (in one aspect, OCF3), thiol, or C2-C6 alkanoyl (in one aspect, C2 alkanoyl); at a therapeutically-active concentration.

### Claim 80 (depends on 79)

A method according to claim 79, wherein the copper-containing amine oxidase is semicarbazide-sensitive amine oxidase.

### Claim 81 (depends on 79)

A method according to claim 79, wherein the animal is a human.

### Claim 82 (depends on 79)

A method according to claim 79, wherein the disease or disorder is an inflammatory disease, an adipocyte dysfunction related disease, a carbohydrate metabolism related disease, a vascular disease, a neurodegenerative disease or cancer.

### Claim 83 (depends on 82)

A method according to claim 82, wherein said inflammatory disease is rheumatoid arthritis, osteoarthritis, spondylitis, bone resorption disease, sepsis, septic shock, chronic pulmonary inflammatory disease, fever, periodontal diseases, ulcerative colitis, pyresis, cystic fibrosis, dysfunctions of the immune system, multiple sclerosis, inflammatory eye conditions including uveitis, glaucoma or conjunctivitis.

### Claim 84 (depends on 82)

A method according to claim 82, wherein said inflammatory disease is degenerative bone or joint conditions including osteoarthritis, rheumatoid arthritis, rheumatoid spondylitis, gouty arthritis ankylosing spondylitis, psoriatic arthritis and other arthritic conditions, or joint inflammation.

### Claim 85 (depends on 82)

A method according to claim 82, wherein said inflammatory disease is a chronic inflammatory skin condition, that is allergic lesions, lichen planus, pityriasis rosea, eczema, psoriasis, or dermatitis.

### Claim 86 (depends on 82)

A method according to claim 82, wherein said inflammatory disease is a disease or disorder of the gastrointestinal tract, that is inflammatory bowel disease, Crohn's disease, atrophic gastritis, gastritis varialoforme, ulcerative colitis, coeliac disease, regional ileitis, peptic ulceration, particularly irritable bowel syndrome, reflux oesophagitis, and damage to the gastrointestinal tract resulting from infections by Helicobacter pylori or other infectious organism or from treatments with non-steroidal anti-inflammatory drugs;

### Claim 87 (depends on 82)

A method according to claim 82, wherein said inflammatory disease is an inflammatory lung disorder that is asthma, bronchitis, particularly chronic obstructive pulmonary disease, farmer's lung, or acute respiratory distress syndrome.

### Claim 88 (depends on 82)

A method according to claim 82, wherein said inflammatory disease is meningitis, pancreatitis, bacteraemia, endotoxaemia (septic shock), aphthous ulcers, gingivitis, pyresis, or pain, comprising inflammatory pain, neuropathic pain, acute pain or pain of a central origin.

### Claim 89 (depends on 82)

A method according to claim 82, wherein said inflammatory disease is a central nervous system inflammatory condition or disease comprising multiple sclerosis, Alzheimer's disease, or ischaemia-reperfusion injury associated with ischemic stroke.

### Claim 90 (depends on 82)

A method according to claim 82, wherein the carbohydrate metabolism related disease is diabetes or a complication of diabetes that is a microvascular or macrovascular disease comprising atherosclerosis, vascular retinopathies, nephropathies, neuropathies, joint problems or foot ulcers.

### Claim 91 (depends on 82)

A method according to claim 82, wherein the adipocyte metabolism dysfunction is obesity or complications thereof comprising diabetes, hypertension or atherosclerosis.

### Claim 92 (depends on 82)

A method according to claim 82, wherein the neurodegenerative disease is Alzheime's disease or Parkinson's disease.

### Claim 93 (depends on 82)

A method according to claim 82, wherein the vascular disease is atheromatous and nonatheromatous arteriosclerosis, ischemic heart disease, or Raynaud's Disease and Phenomenon.

### Claim 94 (depends on 79)

A method according to claim 79, wherein the disease or disorder is atherosclerosis, a neurodegenerative disease, obesity, hypertension or cancer.

### Claim 95 (depends on 43)

A pharmaceutical composition comprising a compound according to claim 43, or a pharmaceutically-acceptable salt thereof and a pharmaceutically-acceptable excipient, diluent or adjuvant thereof.

### Claim 96 (depends on 95)

A pharmaceutical composition according to claim 95, wherein the compound is:
N1-hydroxy-N2-[(4-bromophenyl)carbonyl]glycinamide.

### Claim 97 (depends on 45)

A pharmaceutical composition comprising a compound according to claim 45, or a pharmaceutically-acceptable salt thereof and a pharmaceutically-acceptable excipient, diluent or adjuvant thereof.

### Claim 98 (depends on 97)

A pharmaceutical composition according to claim 97, wherein the compound is:
N-hydroxy-N′-(1-methyl-3-phenylpropyl)succinamide;
N-hydroxy-N′-(2-hydroxyphenyl)succinamide; and
N1-hydroxy-N4-(1-(naphthalen-2-yl)ethyl)succinamide.

### Claim 99 (depends on 51)

A pharmaceutical composition comprising a compound according to claim 51, or a pharmaceutically-acceptable salt thereof and a pharmaceutically-acceptable excipient, diluent or adjuvant thereof.

### Claim 100 (depends on 99)

A pharmaceutical composition according to claim 99, wherein the compound is:
N-hydroxy-4-[({[1-(4-methylphenyl)cyclopentyl]carbonyl}amino)methyl]benzamide;
and
N-hydroxy-4-({[3-(2-hydroxyphenyl)propanoyl]amino}methyl)benzamide.

### Claim 101 (depends on 56)

A pharmaceutical composition comprising a compound according to claim 56, or a pharmaceutically-acceptable salt thereof and a pharmaceutically-acceptable excipient, diluent or adjuvant thereof.

### Claim 102 (depends on 101)

A pharmaceutical composition according to claim 101, wherein the compound is:
N-(biphenyl-4-ylacetyl)glutamic acid;
N5-hydroxy-N2-{[1-(4-methylphenyl)cyclopentyl]carbonyl}glutamine;
N-(4-phenylbutanoyl)glutamic acid;
N-[4-(4-methylphenyl)butanoyl]glutamic acid; and
N-[(2E)-3-(4-methylphenyl)prop-2-enoyl]glutamic acid.

### Claim 103 (depends on 62)

A pharmaceutical composition comprising a compound according to claim 62, or a pharmaceutically-acceptable salt thereof and a pharmaceutically-acceptable excipient, diluent or adjuvant thereof.

### Claim 104 (depends on 103)

A pharmaceutical composition according to claim 103, wherein the compound is:
1-(biphenyl-4-ylcarbonyl)prolinamide;
1-(4-tert-butylbenzoyl)prolinamide;
1-(3-hydroxy-2-naphthoyl)prolinamide; and
1-(quinolin-6-ylcarbonyl)prolinamide.

### Claim 105 (depends on 67)

A pharmaceutical composition comprising a compound according to claim 67, or a pharmaceutically-acceptable salt thereof and a pharmaceutically-acceptable excipient, diluent or adjuvant thereof.

### Claim 106 (depends on 105)

A pharmaceutical composition according to claim 105, wherein the compound is:
5-amino-N-benzyl-2-hydroxybenzamide;
5-amino-2-hydroxy-N-(2-hydroxybenzyl)benzamide;
5-amino-N-(4-fluorobenzyl)-2-hydroxybenzamide;
5-amino-N-(3,5-dimethoxybenzyl)-2-hydroxybenzamide;
5-amino-2-hydroxy-N-(2-naphthylmethyl)benzamide;
5-amino-2-hydroxy-N-(2-phenylethyl)benzamide;
5-amino-2-hydroxy-N-(3-phenylpropyl)benzamide; and
5-amino-2-hydroxy-N-(4-phenylbutyl)benzamide.

### Claim 107 (depends on 71)

A pharmaceutical composition comprising a compound according to claim 71, or a pharmaceutically-acceptable salt thereof and a pharmaceutically-acceptable excipient, diluent or adjuvant thereof.

### Claim 108 (depends on 107)

A pharmaceutical composition according to claim 107, wherein the compound is:
4-amino-N-(4-fluorobenzyl)-3-hydroxybenzamide;
4-amino-3-hydroxy-N-(2-naphthylmethyl)benzamide;
4-amino-3-hydroxy-N-(2-phenoxyethyl)benzamide;
4-amino-3-hydroxy-N-[1-(2-naphthyl)ethyl]benzamide;
4-amino-3-hydroxy-N-(2-phenylethyl)benzamide;
4-amino-3-hydroxy-N-(3-phenylpropyl)benzamide; and
4-amino-3-hydroxy-N-(4-phenylbutyl)benzamide.

### Claim 109

A pharmaceutical composition comprising a compound, or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable excipient, diluent or adjuvant thereof, wherein the compound is selected from:
N-hydroxy-2-(2-(2-methyl-1H-indol-3-yl)acetamido)acetamide;
N-hydroxy-4-({[(4-methylphenyl)sulfonyl]amino}methyl)benzamide;
N-(1H-indol-2-ylcarbonyl)glutamic acid;
1-(isoquinolin-1-ylcarbonyl)prolinamide;
5-amino-2-hydroxy-N-(2-phenoxyethyl)benzamide;
N2-(biphenyl-4-ylsulfonyl)-N1-hydroxythreoninamide;
3-amino-N2-(biphenyl-4-ylsulfonyl)-N1-hydroxyalaninamide;
N1-hydroxy-N2-[(4-propylphenyl)sulfonyl]serinamide;
N1-hydroxy-N2-[(4-propylphenyl)sulfonyl]threoninamide;
N2-{[4-(1,1-dimethylpropyl)phenyl]sulfonyl}-N1-hydroxyserinamide;
N2-{[4-(1,1-dimethylpropyl)phenyl]sulfonyl}-N-hydroxythreoninamide;
N2-{[4-(1,1-dimethylpropyl)phenyl]sulfonyl}-N1-hydroxyglycinamide;
N1-hydroxy-N2-(2-naphthylsulfonyl)serinamide;
N1-hydroxy-N2-(2-naphthylsulfonyl)threoninamide;
N1-hydroxy-N2-[(4-methyl-3-nitrophenyl)sulfonyl]serinamide;
N1-hydroxy-N2-(2-naphthylsulfonyl)glycinamide;
N1-hydroxy-N2-[(4-methylphenyl)sulfonyl]threoninamide;
3-amino-hydroxy-N2-[(4-methylphenyl)sulfonyl]alaninamide;
N1-hydroxy-N2-(quinolin-7-yl sulfonyl)threoninamide;
N2-{[8-(dimethylamino)-2-naphthyl]sulfonyl}-N1-hydroxyserinamide; and
N2-{[8-(dimethylamino)-2-naphthyl]sulfonyl}-N1-hydroxythreoninamide.
